Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Paratek Pharmaceuticals Rose as Much as 16.1% Today

By Maxx Chatsko – Updated May 4, 2017 at 4:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced first-quarter 2017 earnings and provided a clinical update.

What happened

Shares of Paratek Pharmaceuticals (PRTK 10.22%) rose over 16% Thursday after announcing financial results for the first quarter of 2017 and giving investors a regulatory timeline for its lead drug candidate, which, in April, achieved positive phase 3 results for treating community-acquired bacterial pneumonia with an intravenous formulation. An oral formulation of the drug candidate, omadacycline, is also being evaluated in a phase 3 trial for treating acute bacterial skin and skin-structure infections. 

Most importantly for investors, management now believes that it can submit a New Drug Application for each formulation to the U.S. Food and Drug Administration as early as the first quarter of 2018, which is one quarter earlier than previous expectations. As of market close, the stock had settled to a 14.8% gain.

A graph on a chalkboard symbolizing growth.

Image source: Getty Images. 

So what

It goes without saying that submitting an NDA earlier could result in earlier potential marketing approval. Moving up the timeline for potential product sales is especially important for a pre-revenue company such as Paratek Pharmaceuticals. But investors are likely aware that the biopharma company has been on a roll lately throughout its pipeline. Other highlights include:

  • The company announced, together with Allergan, positive phase 3 results for two studies evaluating sarecycline as a treatment for acne. Allergan expects to file an NDA in the second half of 2017.
  • Paratek announced a collaboration with Zai Lab to commercialize omadacycline in China. 
  • It announced positive phase 1 results for omadacycline showing encouraging pharmacodynamic activity in the lungs of patients with community-acquired bacterial pneumonia. In other words, the company has more data providing evidence to support future expanded use of the drug candidate in additional diseases and conditions. 

Thanks to a flurry of news in the last several months, it should be no surprise that Paratek Pharmaceuticals stock has risen over 50% year to date. 

Now what

Long-term investors appear to have a winner on their hands with Paratek Pharmaceuticals, especially at a market cap of around $600 million. The only bad news is that investors have to wait at least one year before revenue arrives, assuming sarecycline and omadacycline are approved. Even then there could be some uncertainty regarding the initial performance of the products. Then again, that's much better than dealing with the uncertainty that comes from failed clinical trials.

Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Paratek Pharmaceuticals, Inc. Stock Quote
Paratek Pharmaceuticals, Inc.
$2.48 (10.22%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.